Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nanobiotix ( (NBTX) ) just unveiled an announcement.
On May 27, 2025, Nanobiotix disclosed transactions by individuals with managerial responsibilities in compliance with the EU Market Abuse Regulation. The notification, dated May 26, 2025, involved the acquisition of shares on Euronext Paris, highlighting the company’s adherence to regulatory standards and transparency in its financial operations.
The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The overall stock score of 43 reflects Nanobiotix’s substantial financial challenges, including declining revenues, negative profitability, and a high leverage ratio. While the strategic partnership with JNJ offers potential future milestones and an extended cash runway, current financial performance and valuation metrics remain under significant pressure. Technical indicators show some positive momentum, but overall stock performance is hindered by underlying financial instability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a company operating in the biotechnology industry, primarily focused on developing innovative nanomedicine products. The company is known for its work in enhancing cancer treatment through its proprietary technology, aiming to improve the efficacy of radiotherapy.
Average Trading Volume: 12,012
Technical Sentiment Signal: Sell
Current Market Cap: $180.2M
For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.